Product Description
Atrasentan is a highly selective ETAR antagonist with an approximate 1800:1 selectivity for ETAR to ETBR (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3065231/)
Mechanisms of Action: ETa Antagonist, Mineralocorticoid Receptor Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Accelerated Approval - IgA NephropathyOrphan Drug - IgA Nephropathy *
Approval Status: Approved
Approved Countries: None
Approved Indications: None
Company: Chinook Therapeutics
Company Location:
Company Founding Year: 2019
Additional Commercial Interests: AbbVie
Clinical Description
Countries in Clinic: Argentina, Australia, Brazil, Canada, China, Colombia, Czech Republic, France, Germany, Hong Kong, India, Ireland, Italy, Japan, Korea, Malaysia, New Zealand, Poland, Portugal, South Korea, Spain, Taiwan, United Kingdom, United States
Active Clinical Trial Count: 12
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Novartis presented P3 Kidney Diseases results on 2026-06-03 for Atrasentan
Highest Development Phases
Phase 3: Glomerulonephritis|IgA Nephropathy|Kidney Failure, Chronic
Phase 2: Diabetic Nephropathy|Glomerulosclerosis, Focal Segmental|Glomerulosclerosis, Nodular|Kidney Diseases|Nephritis, Hereditary
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2023-503828-13-00 |
CHK01-03 | P2 |
Active, not recruiting |
IgA Nephropathy |
2026-05-25 |
2025-05-02 |
Treatments |
|
NCT06841094 |
ASSIST | P2 |
Active, not recruiting |
IgA Nephropathy|Kidney Diseases|Glomerulonephritis |
2025-10-22 |
2025-02-26 |
Primary Endpoints|Treatments |
|
NCT04573920 |
AFFINITY | P2 |
Active, not recruiting |
IgA Nephropathy|Kidney Diseases|Glomerulosclerosis, Focal Segmental|Nephritis, Hereditary|Glomerulosclerosis, Nodular|Diabetic Nephropathy|Glomerulonephritis |
2024-07-02 |
50% |
2024-10-12 |
Primary Completion Date|Primary Endpoints|Start Date|Treatments |
NCT04573478 |
ALIGN | P3 |
Active, not recruiting |
Glomerulonephritis|IgA Nephropathy|Kidney Failure, Chronic |
2028-04-14 |
39% |
2026-06-05 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
2024-513228-40-00 |
CHK01-02 | P2 |
Active, not recruiting |
Glomerulosclerosis, Focal Segmental|Kidney Diseases|IgA Nephropathy |
2025-04-06 |
2025-05-02 |
Treatments |
|
2020-004176-18 |
The AFFINITY Study | P2 |
Active, not recruiting |
Kidney Diseases|Glomerulosclerosis, Focal Segmental|IgA Nephropathy |
2024-02-03 |
2025-05-06 |
Treatments |
|
CTR20212405 |
CTR20212405 | P3 |
Active, not recruiting |
IgA Nephropathy |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
NCT07498335 |
ADVANCE | P3 |
Recruiting |
Kidney Failure, Chronic|IgA Nephropathy|Glomerulonephritis |
2031-09-15 |
30% |
2026-07-15 |
|
jRCT2041260035 |
jRCT2041260035 | P3 |
Not yet recruiting |
IgA Nephropathy |
2031-04-30 |
|||
2024-513227-16-00 |
CHK0101 | P3 |
Recruiting |
IgA Nephropathy |
2027-06-30 |
2025-05-02 |
Treatments |
|
jRCT2071210028 |
jRCT2071210028 | P3 |
Recruiting |
IgA Nephropathy |
2025-08-06 |
|||
NCT05834738 |
ASSIST | P2 |
Completed |
IgA Nephropathy|Glomerulonephritis|Kidney Failure, Chronic |
2025-06-30 |
2026-07-21 |
Primary Endpoints|Treatments |